Suvemcitug
Based on 1 Customer Validation
Suvemcitug (APX-003) is a selective humanized rabbit monoclonal IgG1 (κ) anti-VEGF antibody. Suvemcitug inhibits the binding of VEGF to purified VEGFR1 (IC50 = 21.0 ng/mL) and VEGFR2 (IC50 = 275.4 ng/mL). Suvemcitug suppresses tumor angiogenesis, tumor growth and metastasis. Suvemcitug is applicable to research related to epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
For research use only. We do not sell to patients.
- Purity: 96%
- CAS No.: 1610010-57-5
- Molecular Weight:145.782 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
|
VEGFR1 21.0 ng/mL (IC50) |
VEGFR2 275.4 ng/mL (IC50) |
Suvemcitug potently inhibits the binding of VEGF to purified VEGFR1 (IC50 = 21.0 ng/mL) and VEGFR2 (IC50 = 275.4 ng/mL)[2].
Suvemcitug exhibits stronger anti-proliferative activity against umbilical vein endothelial cells than Bevacizumab (HY-P9906)[2].
Suvemcitug selectively binds to multiple VEGF isoforms (including VEGF164) and potently inhibits the binding of VEGF to VEGFR1 (IC50 = 21.0 ng mL-1) and VEGFR2 (IC50 = 275.4 ng mL-1) in cell-free biochemical assays[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Loaded Suvemcitug on ProA biosensor, can bind HY-P7420 VEGF121 Protein, Human (120a.a) with an affinity constant of 3.500E-11 M as determined in BLI assay.
Chemical Information
-
CAS No. 1610010-57-5
-
Appearance Liquid
-
Molecular Weight 145.782 kDa
-
Color Colorless to light yellow
-
SMILES
[Suvemcitug]
-
Synonyms
APX-003; BD-0801
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ma L, et al. Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage. Invest New Drugs. 2025;43(2):181-190. [Content Brief]
[2]. Mao C, et al. Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials. ESMO Open. 2023;8(3):101540. [Content Brief]
[3]. Yuan G, et al. Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial. Nat Cancer. 2026;7(1):182-193. [Content Brief]
[4]. Yuan G, et al. Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial. Gynecol Oncol. 2024 Aug;187:212-220. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- Suvemcitug
- 1610010-57-5
- APX-003
- BD-0801
- APX003
- APX 003
- BD0801
- BD 0801
- BD-0801
- VEGFR
- VEGFA
- platinum-resistant epithelial ovarian cancer
- hepatocellular carcinoma
- platinum-resistant recurrent ovarian cancer
- VEGFR1/2
- tumor angiogenesis
- mouse VEGFA
- human VEGFA
- metastatic colorectal cancer
- human umbilical vein endothelial cells
- Inhibitor
- inhibitor
- inhibit